{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T09:19:11Z","timestamp":1774775951448,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"M\u00e1ximo Soriano Private Foundation"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.coph.2015.07.004","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T21:30:21Z","timestamp":1438205421000},"page":"45-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["New antibiotics against gram-positives: present and future indications"],"prefix":"10.1016","volume":"24","author":[{"given":"Laura","family":"Morata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Mensa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2015.07.004_bib0310","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1001\/jama.293.24.3012","article-title":"Staphylococcus aureus endocarditis: a consequence of medical progress","volume":"293","author":"Fowler","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2015.07.004_bib0315","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jmb.2008.01.031","article-title":"Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus","volume":"377","author":"Kim","year":"2008","journal-title":"J Mol Biol"},{"key":"10.1016\/j.coph.2015.07.004_bib0320","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1128\/AAC.00760-10","article-title":"Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing","volume":"54","author":"Belley","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0325","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1574-6976.2003.tb00628.x","article-title":"Mechanism of action of oritavancin and related glycopeptide antibiotics","volume":"26","author":"Allen","year":"2003","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.coph.2015.07.004_bib0330","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1086\/648438","article-title":"Telavancin: a novel lipoglycopeptide","volume":"49","author":"Saravolatz","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0335","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1093\/cid\/cir923","article-title":"Oritavancin microbiologic features and activity results from the surveillance program in the United States","volume":"54","author":"Mendes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0340","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1128\/AAC.01453-08","article-title":"Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates","volume":"53","author":"Biedenbach","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0345","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_sbref0350","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0355","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1128\/AAC.00176-15","article-title":"Population pharmacokinetic analysis for a single 1200mg dose of oritavancin using data from two pivotal phase 3 clinical trials","volume":"59","author":"Rubino","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0360","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1093\/cid\/cis001","article-title":"In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans","volume":"54","author":"Ambrose","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_sbref0365","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1093\/cid\/cir921","article-title":"Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin","volume":"54","author":"Baquir","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0370","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1128\/AAC.00766-08","article-title":"Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro","volume":"53","author":"Belley","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0375","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jac\/dki198","article-title":"Telavancin: in vitro activity against staphylococci in a biofilm model","volume":"56","author":"Gander","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0380","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1128\/AAC.01145-08","volume":"53","author":"Nguyen","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0385","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1128\/AAC.01146-08","article-title":"Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations","volume":"53","author":"Nguyen","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_sbref0390","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2015.07.004_bib0395","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_sbref0400","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2015.07.004_bib0405","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0410","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1128\/AAC.50.3.994-1000.2006","article-title":"Pharmacokinetic\u2013pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia","volume":"50","author":"Bhavnani","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0415","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/cid\/cit560","article-title":"The empirical combination of vancomycin and a B-lactam for staphylococcal bacteremia","volume":"57","author":"McConeghy","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0420","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jac\/dkp503","article-title":"Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae","volume":"65","author":"Moisan","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0425","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1128\/AAC.00029-07","article-title":"Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae","volume":"51","author":"Davies","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0430","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/cir147","article-title":"Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"52","author":"Saravolatz","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0435","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1128\/AAC.04614-14","article-title":"Ceftaroline activity against bacterial pathogens frequently isolated in U.S. Medical Centers: results from five years of the AWARE surveillance program","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0440","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1345\/aph.1L016","article-title":"Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin","volume":"42","author":"Anderson","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.coph.2015.07.004_bib0445","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/AAC.01325-09","article-title":"Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus","volume":"54","author":"Nannini","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_sbref0450","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1128\/AAC.00362-12","article-title":"Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 105 and 107 CFU injected into opposite thighs of neutropenic mice","volume":"57","author":"Lee","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0455","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.diagmicrobio.2012.01.015","article-title":"In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: stratified analysis by vancomycin MIC","volume":"73","author":"Chong","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0460","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1128\/AAC.01181-06","article-title":"Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0465","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/jac\/dkp176","article-title":"Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model","volume":"64","author":"Zhanel","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2015.07.004_sbref0470","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1128\/AAC.02611-13","article-title":"Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia","volume":"58","author":"Muller","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0475","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0480","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.coph.2015.07.004_sbref0485","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0490","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1128\/AAC.03652-14","article-title":"Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of ceftaroline fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter","volume":"58","author":"So","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0495","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/jac\/dku236","article-title":"Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes","volume":"69","author":"Barber","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0500","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/dku378","article-title":"The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA","volume":"70","author":"Barber","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2015.07.004_sbref0505","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.coph.2015.07.004_bib0510","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1128\/AAC.02531-14","article-title":"Pharmacokinetic\u2013pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections","volume":"59","author":"Bhavnani","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_sbref0515","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection","volume":"51","author":"Corey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_sbref0520","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2 randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"File","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0525","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1128\/AAC.01748-13","article-title":"Pharmacokinetic\u2013pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia","volume":"57","author":"Bhavnani","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_sbref0530","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(14)71018-7","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial","volume":"15","author":"Zhong","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0535","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0540","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1473-3099(07)70312-2","article-title":"Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials","volume":"8","author":"Falagas","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0545","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/jac\/dkh409","article-title":"Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case\u2013control study","volume":"54","author":"Senneville","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0550","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.2010.757","article-title":"Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit","volume":"303","author":"Garc\u00eda","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2015.07.004_bib0555","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1128\/AAC.01653-09","article-title":"Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain","volume":"54","author":"Betriu","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.coph.2015.07.004_bib0560","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cit616","article-title":"Tedizolid for the management of human infections: in vitro characteristics","volume":"58","author":"Locke","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0565","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1128\/AAC.00663-10","article-title":"Structure\u2013activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations","volume":"54","author":"Locke","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0570","doi-asserted-by":"crossref","first-page":"6592","DOI":"10.1128\/AAC.03493-14","article-title":"Linezolid-resistant Staphylococcus aureus strain 1128105, the first known clinical isolate possessing the cfr multidrug resistance gene","volume":"58","author":"Locke","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0575","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jac\/dkr403","article-title":"In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci","volume":"67","author":"Rodr\u00edguez-Avial","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0580","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1128\/AAC.00859-08","article-title":"In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains","volume":"52","author":"Shaw","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0585","first-page":"243","article-title":"Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections","volume":"7","author":"Urbina","year":"2013","journal-title":"Drug Des Devel Ther"},{"issue":"Suppl 1","key":"10.1016\/j.coph.2015.07.004_bib0590","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/cid\/cit615","article-title":"Use of pharmacokinetic\/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate","volume":"58","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2015.07.004_bib0595","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1128\/AAC.00502-11","article-title":"Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model","volume":"55","author":"Drusano","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0600","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.1128\/AAC.03423-14","article-title":"Tedizolid population pharmacokinetics, exposure-response, and target attainment","volume":"58","author":"Flanagan","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_bib0605","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1128\/AAC.03431-14","article-title":"Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment","volume":"58","author":"Flanagan","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2015.07.004_sbref0610","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.03688-14","article-title":"Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections","volume":"59","author":"Shorr","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"updated-by":[{"DOI":"10.1016\/j.coph.2015.11.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000}}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489215000880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489215000880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:48:38Z","timestamp":1761461318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489215000880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":61,"alternative-id":["S1471489215000880"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2015.07.004","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New antibiotics against gram-positives: present and future indications","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2015.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}